Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:OCAT
- CUSIP: N/A
- Web: www.ocata.com
- 50 Day Moving Avg: $8.42
- 200 Day Moving Avg: $6.15
- 52 Week Range: $3.06 - $8.71
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.29
- P/E Growth: 0.00
- Net Margins: -4,564.66%
- Return on Equity: -103.02%
- Return on Assets: -46.18%
- Average Volume: 830,858 shs.
Frequently Asked Questions for Ocata Therapeutics (NASDAQ:OCAT)
What is Ocata Therapeutics' stock symbol?
Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."
How were Ocata Therapeutics' earnings last quarter?
Ocata Therapeutics Inc (NASDAQ:OCAT) released its earnings results on Thursday, August, 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.01. The business earned $0.04 million during the quarter. Ocata Therapeutics had a negative net margin of 4,564.66% and a negative return on equity of 103.02%. View Ocata Therapeutics' Earnings History.
Who are some of Ocata Therapeutics' key competitors?
Some companies that are related to Ocata Therapeutics include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT) and GW Pharmaceuticals PLC (GWPH).
How do I buy Ocata Therapeutics stock?
Shares of Ocata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocata Therapeutics' stock price today?
MarketBeat Community Rating for Ocata Therapeutics (NASDAQ OCAT)MarketBeat's community ratings are surveys of what our community members think about Ocata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ocata Therapeutics stock can currently be purchased for approximately $8.47.
Consensus Ratings for Ocata Therapeutics (NASDAQ:OCAT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Ocata Therapeutics (NASDAQ:OCAT)
(Data available from 9/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|2/23/2016||Cantor Fitzgerald||Reiterated Rating||Hold||$8.50||N/A|
|11/10/2015||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
Earnings History for Ocata Therapeutics (NASDAQ:OCAT)Earnings History by Quarter for Ocata Therapeutics (NASDAQ OCAT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS
Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ocata Therapeutics (NASDAQ:OCAT)Insider Trades by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/10/2015||Robert Lanza||insider||Sell||35,000||$8.31||$290,850.00|| |
Headline Trends for Ocata Therapeutics (NASDAQ:OCAT)
Latest Headlines for Ocata Therapeutics (NASDAQ:OCAT)
Ocata Therapeutics (OCAT) Chart for Tuesday, September, 26, 2017